Hsbc Holdings PLC Bei Gene, Ltd. Transaction History

Hsbc Holdings PLC

  • $168 Billion
  • Q3 2024

A detailed history of Hsbc Holdings PLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Hsbc Holdings PLC holds 21,370 shares of BGNE stock, worth $4.67 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,370
Previous 24,181 11.62%
Holding current value
$4.67 Million
Previous $3.45 Million 39.08%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$143.93 - $224.51 $404,587 - $631,097
-2,811 Reduced 11.62%
21,370 $4.8 Million
Q2 2024

Aug 12, 2024
SELL
$129.52 - $174.32 $1.81 Million - $2.44 Million
-14,013 Reduced 36.69%
24,181 $3.45 Million
Q1 2024

May 15, 2024
BUY
$141.8 - $181.47 $909,788 - $1.16 Million
6,416 Added 20.19%
38,194 $5.97 Million
Q4 2023

Feb 12, 2024
SELL
$158.67 - $201.58 $5.34 Million - $6.79 Million
-33,685 Reduced 51.46%
31,778 $5.73 Million
Q3 2023

Nov 13, 2023
BUY
$179.87 - $225.13 $4.27 Million - $5.35 Million
23,744 Added 56.91%
65,463 $11.8 Million
Q2 2023

Aug 11, 2023
BUY
$178.3 - $266.78 $816,792 - $1.22 Million
4,581 Added 12.34%
41,719 $7.44 Million
Q1 2023

May 15, 2023
SELL
$215.53 - $274.5 $3.08 Million - $3.93 Million
-14,303 Reduced 27.8%
37,138 $8 Million
Q4 2022

Feb 14, 2023
SELL
$125.51 - $229.3 $4.35 Million - $7.96 Million
-34,693 Reduced 40.28%
51,441 $11.3 Million
Q3 2022

Nov 14, 2022
SELL
$131.8 - $202.24 $2.71 Million - $4.15 Million
-20,527 Reduced 19.25%
86,134 $11.6 Million
Q2 2022

Aug 11, 2022
BUY
$121.11 - $216.05 $2.76 Million - $4.93 Million
22,822 Added 27.22%
106,661 $17.3 Million
Q1 2022

May 16, 2022
BUY
$146.52 - $269.56 $1.2 Million - $2.2 Million
8,162 Added 10.79%
83,839 $15.8 Million
Q4 2021

Feb 11, 2022
SELL
$248.56 - $389.34 $279,630 - $438,007
-1,125 Reduced 1.46%
75,677 $20.5 Million
Q3 2021

Nov 12, 2021
BUY
$249.6 - $403.14 $1.11 Million - $1.79 Million
4,429 Added 6.12%
76,802 $27.9 Million
Q2 2021

Aug 13, 2021
BUY
$292.75 - $367.01 $8.42 Million - $10.6 Million
28,761 Added 65.95%
72,373 $24.8 Million
Q1 2021

May 14, 2021
SELL
$260.64 - $382.12 $3.74 Million - $5.49 Million
-14,357 Reduced 24.77%
43,612 $15.2 Million
Q4 2020

Feb 12, 2021
SELL
$221.31 - $316.61 $92.7 Million - $133 Million
-418,864 Reduced 87.84%
57,969 $15 Million
Q3 2020

Nov 12, 2020
SELL
$189.18 - $286.44 $48.6 Million - $73.6 Million
-257,045 Reduced 35.03%
476,833 $137 Million
Q2 2020

Aug 14, 2020
SELL
$123.9 - $195.41 $772,020 - $1.22 Million
-6,231 Reduced 0.84%
733,878 $138 Million
Q1 2020

May 15, 2020
BUY
$121.84 - $173.19 $39.7 Million - $56.5 Million
325,943 Added 78.7%
740,109 $91.1 Million
Q4 2019

Feb 14, 2020
BUY
$115.78 - $208.34 $40.7 Million - $73.2 Million
351,362 Added 559.46%
414,166 $68.6 Million
Q3 2019

Nov 14, 2019
BUY
$120.61 - $148.29 $734,032 - $902,492
6,086 Added 10.73%
62,804 $7.69 Million
Q2 2019

Aug 13, 2019
SELL
$113.99 - $146.86 $266,736 - $343,652
-2,340 Reduced 3.96%
56,718 $7.03 Million
Q1 2019

May 15, 2019
BUY
$122.82 - $151.83 $6.61 Million - $8.17 Million
53,785 Added 1020.01%
59,058 $7.8 Million
Q4 2018

Feb 13, 2019
SELL
$107.01 - $175.15 $281 Million - $459 Million
-2,623,145 Reduced 99.8%
5,273 $740,000
Q3 2018

Nov 13, 2018
BUY
$152.62 - $189.66 $371 Million - $461 Million
2,428,418 Added 1214.21%
2,628,418 $453 Million
Q2 2018

Aug 10, 2018
BUY
$152.5 - $216.77 $15.3 Million - $21.7 Million
100,000 Added 100.0%
200,000 $30.7 Million
Q1 2018

May 11, 2018
BUY
$97.41 - $177.22 $9.74 Million - $17.7 Million
100,000 New
100,000 $16.8 Million

Others Institutions Holding BGNE

# of Institutions
253
Shares Held
45.3M
Call Options Held
292K
Put Options Held
119K
View Full List

About BeiGene, Ltd.

BGNE Quotes by TradingView
  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $22.7B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email